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Abstract Molybdenum cofactor (Moco) deficiency is a
rare neurometabolic disorder, characterized by neurological
impairment and refractive seizures, due to toxic accumula-
tion of sulfite in the brain. Earlier it was suggested that in
Moco-deficient humans maternal clearance of neurotoxic
metabolites prevents prenatal brain damage. However,
limited data are available about the time profile in which
neurophysiologic deterioration occurs after birth. The
amplitude-integrated electroencephalography (aEEG) is a
bedside method in neonates to monitor cerebral recovery
after hypoxic-ischemic insults, detect epileptic activity, and
evaluate antiepileptic drug treatment. We describe a
chronological series of changes in aEEG tracings in a
neonate with Moco deficiency. He presented with myo-
clonic spasms and hypertonicity a few hours after birth,
however, the aEEG pattern was still normal. Within 2 days,
the aEEG rapidly changed into a burst suppression pattern
with repetitive seizures. After antiepileptic treatment, the
aEEG remained abnormal. In this patient, the normal aEEG
pattern at birth may have been due to maternal clearance of
sulfite in utero. After birth, accumulation of sulfite causes
progressive brain damage, reflected by the progressive
depression of the aEEG tracings. This is in agreement with
the results from a Moco-deficient mouse model, suggesting
that maternal sulfite clearance suppresses prenatal brain
damage. To our knowledge, this is the first case report
describing the chronological changes in the aEEG pattern in
a Moco-deficient patient. Insight into the time profile in
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which neurologic deterioration in Moco-deficient humans
occurs is essential, especially when potential treatment




cPMP Cyclic pyranopterin monophosphate
CSF Cerebrospinal fluid
MRI Magnetic resonance imaging
Introduction
Molybdenum cofactor (Moco) deficiency is an autosomal-
recessive inherited disorder leading to a combined defi-
ciency of sulfite oxidase, xanthine dehydrogenase, and
aldehyde oxidase. Deficiency of sulfite oxidase leads to
toxic sulfite accumulation in the brain, causing severe
neurological impairment and refractive seizures. In spite of
novel antiepileptic drugs, prognosis remains poor due to
progressive neurodegeneration (Johnson and Duran 2001).
Currently, an effective therapy is only available for type A
of the disease caused by mutations in the MOCS1 gene
(Reiss and Johnson 2003).
The amplitude-integrated EEG (aEEG) is a clinical
bedside system to monitor the electrocortical neuronal
activity. Mostly, it is used in neonatal intensive care units
for the evaluation of cerebral recovery after hypoxic-
ischemic insults, the detection of epileptic activity, and the
evaluation of antiepileptic drug treatment. Due to its
simplicity a non-expert can be trained to recognize the
different aEEG patterns (Hellstrom-Westas and Rosen
2006).
Results from a Moco-deficient mouse model suggest
that maternal sulfite clearance suppresses prenatal brain
damage (Reiss et al. 2005). Therefore, it is hypothesized
that in Moco-deficient humans there is no or only
moderate brain damage present at birth, but damage can
develop due to progressive accumulation of toxic sub-
stances. To our knowledge, limited data are available
about the time profile over which neurophysiologic
deterioration occurs. In this case report we describe a
chronological series of changes in aEEG tracings in a
neonate with Moco deficiency.
Case report
A term male infant (39 weeks and 6 days of gestation) was
delivered after an uneventful pregnancy and uncomplicated
delivery with a birth weight of 3,975 g (75th percentile). He
was the fourth child of consanguineous Afghan parents.
The parents and the three older siblings are all healthy.
Because of myoclonic movements a few hours after birth,
he was transferred to the neonatology unit of our hospital
on day 1 of life. He had mild dysmorphic features including
bilateral microphthalmia, and a wide nasal bridge. On
neurological examination a high pitched cry was noticed,
together with hypertonicity, decreased spontaneous move-
ments and frequent myoclonic spasms. Biochemical inves-
tigations revealed elevated levels of serum lactate
(5.7 mmol/l) and creatine kinase (7500 IU/l). Serum
electrolytes and glucose were all in normal range. A
possible infectious cause of the symptoms was treated with
intravenously administered antibiotics and acyclovir for
48 h, until blood and cerebrospinal (CSF) fluid cultures and
PCR for herpes in CSF were negative. In addition,
metabolic investigation of blood and urine samples was
performed, as well as blood analysis for genetic and
chromosomal abnormalities. Ophthalmologic examination
and cranial ultrasound were performed on admission and
showed no abnormalities. A two-channel aEEG (BrainZ,
Natus Medical, San Carlos, CA, USA) was started to
evaluate a possible epileptic cause for the myoclonic
spasms. However, a continuous normal voltage pattern
with sleep-wake cycling without generalized epileptic
activity was demonstrated (Fig. 1a).
On day 2, metabolic investigation revealed elevated
levels of L-sulfocysteine, hypoxanthine, and xanthine, in
combination with decreased uric acid in both plasma and
urine, suggesting Moco deficiency. Clinical symptoms
persisted, and the aEEG pattern changed from a
continuous normal voltage pattern, via a discontinuous
normal pattern into a burst suppression pattern. As the
aEEG should be used as a complement to a standard
electroencephalogram (EEG), a standard EEG was per-
formed on day 2. It showed a burst suppression pattern
with multifocal abnormalities, but no signs of epileptic
activity at that moment (Fig. 1e). The cranial ultrasound
showed a high echogenic signal in the white matter,
representing white matter edema.
On day 3, the patient developed tonic-clonic seizures, and
the aEEG showed electrographic correlation of repetitive
seizure activity (Fig. 1b). Because of respiratory insufficiency,
he was intubated and mechanically ventilated. Although
treatment with phenobarbitone as antiepileptic drug was
initiated, seizures continued. After the administration of
midazolam (Fig. 1b, c), lidocaine, and pyridoxine, epileptic
activity was suppressed. A flat trace pattern on the aEEG was
registered (Fig. 1d). Magnetic resonance imaging (MRI) at
day 3 showed marked white matter abnormalities and basal
ganglia signal changes (Fig. 2).
From day 5 onwards, vigabatrin was started as an
attempt for maintenance therapy. To reduce excessive
sulfite levels, cysteamine was administered. Midazolam
was diminished and subsequently stopped. The aEEG
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aFig. 1 Raw signal EEG traces(top two rows in a–d) and aEEG
traces (bottom two rows in a–d)
of neonate with Moco deficien-
cy. a Day 1. Continuous normal
voltage pattern with sleep-wake
cycling without any seizures. b
Day 3. Early morning, discon-
tinuous pattern with repetitive
seizures (arrows indicate
administration of phenobarbi-
tone and midazolam). c Day 3,
morning. Not dense burst sup-
pression pattern with repetitive
seizure activity. d Day 3, even-
ing. Flat trace EEG. e Standard
EEG performed on day 2. Burst
suppression pattern with multi-
focal abnormalities. No signs of
epileptic activity
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Fig. 1 (continued)
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showed a continuous low voltage pattern with sporadic
seizures. On day 11, the infant was weaned from
mechanical ventilation. A few hours after detubation, the
infant suffered from sudden unexplained respiratory and
circulatory insufficiency, and resuscitation was started.
However, despite maximum resuscitation, bradycardia
persisted and the patient deceased. The parents did not
give their consent for complete autopsy.
In our patient, the genotype analysis for Moco deficiency
showed homozygosity for the novel mutation c.220C>T in
exon 3 of the MOCS2 gene. Both parents are heterozygous
carriers of this mutation. This mutation is located in the
overlapping region of the two open reading frames in the
MOCS2 gene. In the 3′ reading frame for the large subunit
of molybdopterin synthase the identified mutation is silent.
In the 5′ reading frame, however, the creation of a stop
codon abolishes the highly conserved double glycin
terminus of the small subunit. The identification of this
clearly pathogenic mutation in the MOCS2 gene confirms
the diagnosis of a Moco deficiency type B.
Discussion
In this case report, we describe the chronological changes
in the aEEG in a patient with Moco deficiency type B.
He presented with signs of hypertonicity and myoclonic
spasms shortly after birth. The aEEG at birth showed a
normal background pattern with sleep-wake cycling
without generalized epileptic activity. During the second
day of life the aEEG changed from a continuous normal
voltage pattern, via a discontinuous normal voltage
pattern into a burst suppression pattern, possibly reflect-
ing the progressive brain damage resulting from toxic
sulfite accumulation. On the third day, aEEG showed
status epilepticus, and after treatment a continuous low
voltage registration with sporadic single seizures per-
sisted. After discontinuation of midazolam, background
pattern did not recover, reflecting severe brain damage
(van Leuven et al. 2004).
The aEEG is based on a time-compressed semiloga-
rithmic display of the peak-to-peak amplitude values of a
filtered and rectified EEG signal. The number of
channels differs between monitors. Hellstrom-Westas
and Rosen (2006) suggested a new classification system
for aEEG tracings suiting both term and preterm infants,
describing three categories: background pattern (continu-
ous, discontinuous, burst suppression, low voltage, or
inactive/flat), sleep-wake cycling (absent, immature, or
developed), and seizures. The aEEG can be used for the
detection of seizures and evaluation of antiepileptic
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duration may be missed with aEEG due to the reduced
number of electrodes (Toet et al. 2002). Therefore, it should
always be used as a complement to the standard EEG.
Moco deficiency is a rare autosomal-recessive
inherited disorder leading to a combined deficiency of
sulfite oxidase, xanthine dehydrogenase, and aldehyde
oxidase. Absence of sulfite oxidase leads to sulfite
accumulation and toxicity, causing severe neurologic
impairment. Most affected infants are born after an unevent-
ful pregnancy and delivery. More than 90% develop
symptoms after several days; the others suffer from late
onset disease after the neonatal period. Clinical symptoms
include seizures refractive to therapy, myoclonic spasms,
axial hypotonia, hypertonicity, and feeding difficulties
(Johnson and Duran 2001).
Laboratory investigations usually reveal decreased se-
rum levels of uric acid and increased excretion of sulfite,
thiosulfate, S-sulfocysteine, taurine, hypoxanthine, and
xanthine in urine. Cranial ultrasound imaging and MRI
generally show subcortical cystic formation and atrophy
(Serrano et al. 2007; Teksam et al. 2005).
Moco is synthesized in a multi-step biosynthetic path-
way (Fig. 3). Four human genes are required for this
pathway (MOCS1, MOCS2, MOCS3, and GEPH). Most
pathogenic mutations have been identified in MOCS1 and
MOCS2 (Reiss et al. 2005). Figure 3 shows a schematic
presentation of human Moco biosynthesis, the involved
gene products, and classification of Moco deficiency
(Schwarz et al. 2009). Sulfite oxidase activity can be
assayed in chorionic villus sampling tissue for use in
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Fig. 3 Schematic pathway of Moco biosynthesis. Based on genetic and biochemical analysis, three types of Moco deficiency can be distinguished
(Schwarz et al. 2009)
Fig. 2 T2-weighted (TR 3,000 ms, TE 120 ms; a and b), and T1-
weighted (TR 480 ms, TE 14 ms; c and d) images of Moco-deficient
neonate on 3rd day of life, showing loss of grey to white matter
differentiation and changes in signal intensities in the basal ganglia.
Furthermore, extensive restricted diffusion is seen in the subcortical
white matter and the cortex on the diffusion-weighted images (TR
3,400 ms, TE 122 ms, b 1,000 s/mm2; e and f)
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prenatal diagnosis. Gene-based prenatal diagnosis is more
informative than metabolite assays but should only be used
in families in whom the affected gene and specific defect
have been characterized (Johnson 2003).
Several attempts have been made to reduce sulfite
production by dietary intervention or to absorb excessive
sulfite with, for example, cysteamine administration.
Seizures are often therapy resistant, however, with the
introduction of novel antiepileptic drugs such as vigaba-
trin, seizure control has been observed in some patients
(Johnson and Duran 2001). In 2004 Schwarz et al.
described that repeated injections with cyclic pyranopterin
monophosphate (cPMP, previously identified as precursor Z)
into MOCS1-deficient mice resulted in extension of life span
and normal development of these mice (Schwarz et al. 2004;
Schwarz et al. 2009). Recently, the first patient with Moco
deficiency type A was successfully treated according to this
scheme (Veldman et al. 2010).
Until now, limited data have been available about the
time profile in which neurological deterioration starts in
patients with Moco deficiency. In a MOCS1-deficient
mouse model it was demonstrated that these animals were
indistinguishable from healthy littermates at birth, suggest-
ing a maternal compensation for affected embryos in utero
(Reiss et al. 2005). However, postnatally they fail to thrive
and die within the first 12 days after birth, with an average
life span of 7.5 days. Mice substituted with cPMP reached
adulthood and had normal fertility, but withdrawal of cPMP
from these MOCS1-deficient mice caused death within 10–
14 days (Schwarz et al. 2004). Serrano et al. (2007)
described chronological changes of cranial ultrasound
images in a full term boy with Moco deficiency. Early
cranial ultrasound showed nonspecific brain edema at day 3
and 5, followed by white matter signal changes and cortical
reduction at day 12.
To our knowledge, this is the first case report describing the
chronological changes in the aEEG in a patient with Moco
deficiency type B. Although MRI and routine EEG were not
performed at birth, significant brain damage at day 1 seems
unlikely, as reflected by the normal aEEG pattern and normal
cranial ultrasound findings at birth (Wezel-Meijler et al.
2010). In this patient, it is conceivable that maternal
clearance of the neurotoxic metabolites was sufficient to
protect the brain from severe injury. However, in the absence
of such maternal clearance, there is accumulation of sulfite
which in turn leads to permanent brain injury as shown by
the progressive deterioration of the aEEG pattern. With the
possibility of gene-based prenatal diagnosis of Moco
deficiency and a possible treatment with injections of cPMP
(for type A), insight into the time profile in which neurologic
deterioration in Moco-deficient humans occurs or can be
prohibited is essential.
Acknowledgements We thank the Department of Clinical Neuro-
physiology of the VU University Medical Center for providing the
EEG.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Hellstrom-Westas L, Rosen I (2006) Continuous brain-function
monitoring: state of the art in clinical practice. Semin Fetal
Neonatal Med 11:503–511
Johnson JL (2003) Prenatal diagnosis of molybdenum cofactor
deficiency and isolated sulfite oxidase deficiency. Prenat
Diagn 23:6–8
Johnson JL, Duran M (2001) Molybdenum cofactor deficiency and
isolated sulfite oxidase deficiency. In: Scriver CR, Beander AL,
Valle D, Sly WS (eds) The metabolic & molecular bases of
inherited disease. McGraw-Hill, New York, pp 3163–3177
Reiss J, Johnson JL (2003) Mutations in the molybdenum cofactor
biosynthetic genes MOCS1, MOCS2, and GEPH. Hum Mutat
21:569–576
Reiss J, Bonin M, Schwegler H et al. (2005) The pathogenesis of
molybdenum cofactor deficiency, its delay by maternal clearance,
and its expression pattern in microarray analysis. Mol Genet
Metab 85:12–20
SchwarzG, Santamaria-Araujo JA,Wolf S et al. (2004)Rescue of lethal
molybdenumcofactor deficiency by a biosynthetic precursor from
Escherichiacoli.HumMolGenet13:1249–1255
Schwarz G, Mendel RR, Ribbe MW (2009) Molybdenum cofactors,
enzymes and pathways. Nature 460:839–847
Serrano M, Lizarraga I, Reiss J et al. (2007) Cranial ultrasound and
chronological changes in molybdenum cofactor deficiency.
Pediatr Radiol 37:1043–1046
Teksam O, Yurdakok M, Coskun T (2005) Molybdenum cofactor
deficiency presenting with severe metabolic acidosis and intra-
cranial hemorrhage. J Child Neurol 20:155–157
Toet MC, van der Meij W, de Vries LS, Uiterwaal CS, van Huffelen
KC (2002) Comparison between simultaneously recorded ampli-
tude integrated electroencephalogram (cerebral function monitor)
and standard electroencephalogram in neonates. Pediatrics
109:772–779
van Leuven K, Groenendaal F, Toet MC et al. (2004) Midazolam and
amplitude-integrated EEG in asphyxiated full-term neonates.
Acta Paediatr 93:1221–1227
Veldman A, Santamaria-Araujo JA, Sollazzo S et al. (2010)
Successful treatment of molybdenum cofactor deficiency type A
with cPMP. Pediatrics 125:e1249–e1254
Wezel-Meijler G, Steggerda SJ, Leijser LM (2010) Cranial ultraso-
nography in neonates: role and limitations. Semin Perinatol
34:28–38
J Inherit Metab Dis (201 ) 3 (Suppl 3):S401–S4070 3    S407
